Alcoholic liver disease is an important health problem in the US. A public health approach is proposed, using laboratory tests to identify patients with early fibrosis of the liver. A variety of serologicalmarkers of liver fibrosis based on collagen-related products (e.g., amino-terminal 
tients, treatment does not reduce the prevalence of cirrhosis (6).
A public health strater for alcoholic liver disease would identify patients at high risk of developing cirrhosis and its complications and would refer such patients for abstinence-promoting therapy (6) . Several studies have reported that early medical intervention can be effective in promoting abstinence (7) (8) (9) . In addition, alcoholic patients at high risk of developing cirrhosis may be candidates for protocols that evaluate the efficacy of agents potentially capable of attenuating alcohol-mediated fibrosis (6) . Because clinical identification of such patients is suboptimal, a public health approach requires the development of reliable screening tests based on the pathogenesis of alcoholic liver disease. Besides identifying precirrhotic and cirrhotic lesions, laboratory tests have at least two other important roles in alcoholic liver disease, namely, excluding nonalcoholic liver diseases and monitoring sobriety.
Staging Uver DIsease Markers of Fibrosis 3)(25) . Several studies have further reported that serum concentrations of P-Ill-P correlated with both fibrosis and inflammation scores from liver biopsy samples of alcoholic patients (25, 28) .
However, serum P-Ill-P does not differentiate between alcoholics with PYF and those with simple steatosis (Fig. 3) (25) .
One reason for the limited diagnostic discrimination of the P-Ill-P RIA may be the factthat the assay mainly detects the intact aminopropeptides rather than the S S $ :4
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3. 
Markers of Injury and Necrosis
Liver cell necrosis is an important factor in the progression of liver disease (14). However, the activities of serum liver enzymes such as AST or GGT are not highly S correlated with the magnitude of liver injury (40, 41). As previously discussed, serum P-HI-P and laminin correlate with both fibrosis and necrosis scores (25, 28). Another laboratory marker of necrosis is plasma glutamate dehydrogenase, a mitochondrial enzyme predominantly located in the perivenular area of the hepatic lobule (42). Plasma concentrations of this enzyme correlate with hepatic necrosis scores in alcoholic patients undergoing liver biopsy (Fig. 5) (41, 43) . Because its values decay rapidly in plasma during abstinence, this enzyme, for optimal diagnostic utility, should be measured within 48 h of a patient's last drink (41).
PrognosticMarkers of AdvancedAlcoholicLiver Disease
Other currently used tests such as the bilirubin, prothrombin time, and albumin also fail to detect early fibrosis. As summarized in Table 1 , some of these tests do have utility as components of prognostic indices for patients with advanced alcoholic liver disease (44) (45) (46) hepaticcollagen (115, 116) .
The clinical application of acet.aldehyde adducts as markers of alcoholism requires highly sensitive assays. An ELISA recently developed to detect serum acetaldehyde-proteinadducts found them present in 71% of recentlydrinkingalcoholics; moreover,they persisted for as long as 2 weeks in some patients (117) . Further characterization of these adducts suggested that the protein components were distinct from albumin (117 (82) ; usedwithpermission. terplot of CDT values from a multiethnic population study at the Bronx Veterans Affairs Medical Center is shown in Fig. 6 (137) . Furthermore,
CDT values in recently drinking
alcoholic patients are not related to severity of liver disease (Fig. 7) 
Cost Savings of Laboratory Tuts in Alcoholic Uver Disease
The treatment of alcoholic liver disease and its complications is costly. In patients with bleeding esophageal varices, the costs of endoscopic variceal sclerotherapy and portacaval shunt surgery are -$23 000 and $28 000, respectively (149) . Costs of liver transplant may exceed $200 000 (150) . Use of the public health approach to alcoholic liver disease by using laboratory #{149} tests to identify patients with early fibrotic liver disease assumes that some alcoholic patients will stop drinking if informed that they are at high risk of developing cirrhosis. 
